ANL

F-3/A - Adlai Nortye Ltd. (0001944552) (Filer)

F-3/A - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses. The oversubscribed transaction includes participation from both new and existing institutional investors. New investors include Soleus Capital, Perceptive Advisors, ADAR1 Capital Man

20-F - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

Leerink Partners initiated coverage of Adlai Nortye Ltd. with a rating of Outperform and set a new price target of $23.00

F-3 - Adlai Nortye Ltd. (0001944552) (Filer)

H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor. The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted

SCHEDULE 13G - Adlai Nortye Ltd. (0001944552) (Subject)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities purchase agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses. In the private placement, the Company is selling 64,615,386 Class A ordinary shares of the Company (equivalent of 21,538,462 American Depositary Shares, each representing 3 Class A o

SCHEDULE 13G - Adlai Nortye Ltd. (0001944552) (Subject)

DENVER, Dec. 29, 2025 (GLOBE NEWSWIRE) -- U.S. equity markets head into the session with a familiar late-cycle mix: capital formation stories, platform expansion in high-growth regions, and strategic deal chatter tied to AI, infrastructure, and healthcare. From an OTC microcap grabbing national airtime to Nasdaq-listed companies securing enterprise AI mandates, today's narrative is about positioning for the next leg of secular growth. Xeriant (OTCQB:XERI): National Spotlight Meets Skunk Works Ambition Xeriant, Inc. (OTCQB:XERI) finds itself in rarefied air after Brig. Gen. (Ret.) Blaine D. Holt, recently appointed President and head of the company's Factor X Research Group, appeared on a

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025. Under the terms of the agreement, ASK Pharm will obtain exclusive rights to develop, manufacture, and commercialize AN9025 in mainland China, Hong Kong and Macao (the "Licensed Territory"). Adlai Nortye will retain worldwide rights to the compound excluding the Licensed Territory. Adlai Nortye is elig

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate in the following investor conferences: The 8th Annual Evercore Healthcare ConferenceFormat: Fireside ChatHost: Jonathan MillerDate and Time: Tuesday, December 2, 2025; 4:15 pm - 4:35 PM EST.Location: Sevilla A, Track 2, the Loews Coral Gables Hotel in Coral Gables, Florida. The 36th Oppenheimer Annual Healthcare Life Sciences ConferenceFormat: Virtual Presen

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Key highlights of the presentation include: AN4035 demonstrated strong intracellular payload retention, driving nanomolar to picomolar cytotoxicity in CEACAM5-positive/RAS-addicted cancer cell lines, along with a potent bystander-killing effect

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Presentation details are as follows: Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window Date and Time:

S-8 - Adlai Nortye Ltd. (0001944552) (Filer)